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Abstract
Background Information on costs of managing adverse
events (AEs) associated with current treatments in meta-
static melanoma is limited. This study estimates costs of
AEs in eight countries: Australia (AU), Canada (CA),
France (FR), Germany (GE), Italy (IT), the Netherlands
(NL), Spain (ES), and the UK.
Methods A literature search was conducted to identify
grade 3/4 AEs from product label, published trials, con-
ference abstracts, and treatment guidelines. Resource uti-
lization for the management of each type of AE was
determined via interviews with 5 melanoma clinicians in
each country. Outpatient and inpatient costs were estimated
for each type of AE using country-specific tariffs or gov-
ernment/published sources.
Results In outpatient settings, the most costly AEs per
incident included cutaneous squamous cell carcinoma
(CSCC) (€1063, £720; NL/UK), anemia (€1443, €1329,
€1285; ES/IT/FR), peripheral neuropathy (€1289; ES), and
immune-related diarrhea (AUS$1,121; AU). In inpatient
settings, the most costly AEs per hospitalization included
hypophysitis (€10,265; €5316; CAN$9735; AUS$7231:
ES/FR/CA/AU), dyspnea (€9077; GE), elevated liver
enzymes (€6913, CAN$8030, AUS$6594; FR/CA/AU),
CSCC (CAN$8934; CA), peripheral neuropathy (€6977,
€4144, CAN$9472; NL/ES/CA), and diarrhea (£4284,
€4113; UK/ES).
Conclusions Costs of managing AEs can be significant,
and thus effective treatments with lower rates of severe
AEs would be valuable.
Keywords Adverse drug event  Melanoma  Costs and
cost analysis  Cost of illness
JEL Classification L19
Background
Melanoma is a globally significant condition, with
approximately 200,000 incident melanoma skin cancers
and an estimated 46,000 fatalities occurring from advanced
forms of the disease in 2008 [1]. About 85 % of these
melanoma cases occur in developed countries and repre-
sent the sixth most commonly diagnosed cancer (5.6–39.3
per 100,000), with regions such as North America, Europe,
and Australia reporting the highest incidence rates in the
world [1]. Throughout recent years, the age-standardized
incidence rate of melanoma has continued to increase
approximately 4–6 % per year in European countries such
as the UK, France and Germany [2]. As melanoma con-
tinues to impact growing numbers of individuals, the
potential treatment options and associated economic con-
sequences will require careful consideration.
Prior to the introduction of newer treatments for meta-
static melanoma in 2011, progress in melanoma treatment
had been slow and survival rates had essentially been
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unchanged for decades. Before the introduction of the newer
agents, nearly all patients with regional or distant metastases
were treated with on-label and off-label older conventional
agents as monotherapy or in combinations and regimens.
Three of the most commonly used older conventional agents
are dacarbazine (DTIC), fotemustine (only in some countries
in Europe) and interleukin-2 (IL-2) (only in the US) [3, 4].
Notably, none of these treatments has demonstrated a clini-
cally meaningful improvement in overall survival in a ran-
domized controlled trial (RCT), and none of these options
has been shown to be a superior option [5].
In recent years, significant progress has been made in
the fight against metastatic melanoma. Since 2011, six
agents have been approved for the treatment of advanced
melanoma: ipilimumab, a CTLA-4 antibody; two BRAF
inhibitors, vemurafenib and dabrafenib, a MEK inhibitor,
trametinib, available for patients with BRAF-mutant mel-
anoma, which occurs in 40–50 % of patients with mela-
noma; pembrolizumab and nivolumab, PD-L1 inhibitors,
were approved in the second half of 2014, and were not yet
available at the time this study was conducted [6, 7].
While chemotherapy and IL-2 treatments are most likely
to lead to hematologic toxicities such as neutropenia or
anemia, BRAF inhibitor studies show greater rates of
squamous cell carcinomas and/or keratoacanthoma, and
grade 3 or 4 adverse events with the MEK inhibitor treat-
ment include hypertension and rash. Treatment with ipili-
mumab is associated with a number of grade 3 and 4
adverse events, the majority of which are immune-related,
which may involve the gastrointestinal, liver, skin, ner-
vous, endocrine, ocular, or other organ systems [8].
Although trial data demonstrate the extent of AEs
experienced on each course of therapy, the economics of
managing AEs around the world is not well understood,
especially given the different AE profiles from newer
therapies. Therefore, this study explores the costs in Italy,
Spain, Germany, France, the Netherlands, the UK, Canada,
and Australia related to managing the more frequent ther-
apy-related toxicities to better understand the burden of
AE-related economic impact.
Methods
This study estimates payer perspective costs associated
management of AEs occurring while patients receive
treatment with monotherapy agents that are approved for
use and/or referenced in treatment guidelines for first or
second line treatment of metastatic melanoma in any of the
included countries [9–14]. Products include dacarbazine or
DTIC, temozolomide, fotemustine, IL-2, ipilimumab,
vemurafenib, dabrafenib, and trametinib. The approach
included three steps: (1) identification of toxicities and
their rates; (2) detailed interviews with five clinical experts
per country to determine a potential range of resource
utilization for AE management per setting; and (3) iden-
tifying unit costs per resource and calculating total AE
costs in each country from a public payer perspective.
AE identification
Appropriate clinical studies from which to identify a list of
severe (grade 3 or 4) adverse events associated with the
treatment options of interest were collected via a literature
search. Searches were conducted in PubMed, and addi-
tional information was provided by publicly available
sources from relevant professional conferences, and
materials referenced in product prescribing information.
Search terms included the drug name (dabrafenib, dacar-
bazine or DTIC, fotemustine, ipilimumab, interleukin-2,
temozolomide, trametinib and vemurafenib) along with
‘‘melanoma’’ and ‘‘metastases’’ or ‘‘metastatic’’ or ‘‘ad-
vanced’’, and ‘‘clinical trial’’. In order to ensure the study
captured all relevant AEs across considered therapies, the
highest-quality study was selected for each therapy by line
of treatment (first line, second line, or in cases where no
second line option was available, mixed line). Study
selection criteria prioritized phase 3 studies (unless no
phase 3 studies were available), large sample size, and the
use of a guideline-recommended dosing regimen. This was
done to ensure that AEs were treatment-related, which may
be less clear in earlier-phase studies. Severe adverse
events, grade 3 and 4 as defined by the National Cancer
Institute (NCI) Common Terminology Criteria for Adverse
Events (CTCAE), were identified in the selected studies.
Any AEs reported in less than 1 % of patients across all
selected studies were excluded from the analysis, and
additional abnormal lab value AEs were excluded follow-
ing the first two clinical expert interviews upon indication
that no active management would occur. Resource uti-
lization responses during these first two interviews also
supported grouping AEs by general treatment approach or
degree of management required for later costing, although
this did not affect the interviews. An interview guide
containing the final list of AEs was compiled by type of
therapy to allow clinicians to provide resource utilization
answers according to AE etiology where relevant.
Resource utilization pattern identification
A total of five melanoma clinical experts were interviewed
in each country to document their professional manage-
ment of each AE. Initially, experts were approached if they
had recent publications in the field of advanced/metastatic
melanoma, melanoma society or conference participation;
some participants were identified with the assistance of
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recruiting services. Physicians were required to treat at
least 5 cases of advanced/metastatic melanoma per month;
this number was chosen to allow participation in countries
with lower melanoma treatment density (e.g. Italy,
Canada), although 10–20 cases per month were preferred in
other countries (e.g. Australia, Germany). The individuals
were experienced in the fields of medical oncology or
dermatology.
For each grade 3 or 4 AE per therapy type in the
interview guide, physicians were asked to provide details
for how they would treat each event. The interview guide
was arranged by therapy type, with a list of drugs for which
each adverse event occurred to allow physicians to note
whether AE treatment would differ by melanoma therapy.
Specific questions were translated into local language in
Germany, Italy, and Spain, capturing the English-language
questions of ‘‘what percentage of the time would you
hospitalize a patient with this AE,’’ ‘‘for how long would
patients be hospitalized’’ and ‘‘for those patients not hos-
pitalized, what outpatient resources would you use: what
kinds of tests, procedures or drugs would you recommend,
and at what doses or frequencies?’’ All other interviews
were conducted in English.
Expert responses from the five physicians in each country
were collated to determine the base case approach. Given an
AE without a definitive majority (at least three out of five
physicians in agreement), agreement between two out of five
physicians was used as the default, if the other physician
responses differed. Resources with different names but the
same indication were considered to constitute physician
agreement (e.g. ‘‘oral steroid therapy’’ or ‘‘oral anti-emetic
therapy’’ regardless of specific drug name). Sensitivity
analysis calculationswere conducted by using any additional
or different resources mentioned by clinical experts. In some
settings, physicians were reluctant to provide resource use
for adverse events they never see in their patients. This was
likely because in clinical practice, physicians managed AEs
at a lower grade, prior to grade 3 or 4 severity. Results note
where this was the only response available.
Unit costing
Unit costs for required resources identified by clinical
experts were collected according to a public payer per-
spective. All costs were obtained in 2013 local currency
and are inflated to 2014 local currency [15–17]. For com-
pleteness of data collection, all inpatient costs were
recorded even if physicians unanimously agreed that the
patient would not be hospitalized for that AE. A diagnosis-
related group (DRG) encompassing the relevant condition
was selected where no DRG existed to manage a specific
toxicity. In the outpatient setting, costs were identified for
medications, procedures, and physician consultations.
In Italy, inpatient costs were an average of the six most
populous provinces in Italy using the regional tariffs per
DRG. The provinces were Piemonte, Lombardia, Veneto,
Lazio, Sicilia and Campania. The most recent tariffs were
published in 2009 by the Agenzia Nazionale per i Servizi
Sanitari Regionali (AgeNaS), and were assumed therefore
to be in current use without further tariff inflation [18]. The
outpatient costs were also average regional tariffs from
AgeNaS [19]. The costs for platelets and blood used in
transfusions came from the Ministero della Salute [20]. Ex-
factory drug prices were obtained from the Agenzia Ital-
iana del Farmaco [21].
In Spain, outpatient and inpatient costs were obtained
from the OBLIKUE database, which collects all healthcare
costs available in Spain, both from government databases
and from the literature, and designates the best available
cost information per indication [22]. As the government
collects limited cost information, while government values
were preferred, if unavailable, the best literature source
was used. Drug prices were collected from the Ministry of
Health’s INTEGRA database [23].
In Germany, the inpatient costs were derived from the
Universita¨tsklinikum Mu¨nster, using the DRG Research
Group Medizinisches Management search tool [24]. The
outpatient costs came from The Kassena¨rztliche Bun-
desvereinigung Einheitlicher Bewertungsmaßstab (EBM),
which is maintained by the Ambulatory Care Committee, a
part of the Federal Joint Committee [25]. The prescription
drug costs were derived from the Barmer GEK
Arzneimittelreport and Lauertaxe database [26, 27]. The
Arzneimittelreport was used to determine the most com-
mon drug for a specific indication and the Lauertaxe
database was used to determine the price of the drug.
French inpatient and drug costs were found in public
price lists maintained by the Agence Technique de l’in-
formation sur l’Hospitalisation (ATIH) [28]. Outpatient
procedure costs were from the Se´curite´ Sociale l’Assurance
Maladie en ligne Classification Commune des Actes
Me´dicaux, and lab costs were from the Se´curite´ Sociale
l’Assurance Maladie en ligne Table Nationale de codage de
Biologie [29, 30].
In the Netherlands, the Tariefapplicatie from the Dutch
Healthcare Authority (NZa) was used to identify inpatient
and outpatient costs [31]. This source provides costs for
different hospitals, so the lowest cost was selected for this
exercise. Costs for consultations were from the Institute for
Medical Technology Assessment at Erasmus University
[32]. The cost for oxygen was from Praxisdienst [33].
Z-Index provided drug costs except in cases where prod-
ucts were not listed, in which case costs were obtained
from Medicijnkosten [34, 35].
In the UK, inpatient, short stay, and outpatient costs
came from the National Health Service (NHS) National
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Schedule of Referenced Costs, which reflect the average
actual costs to the hospital to provide the activity, and is the
preferred source for payer perspective costs in the UK [36].
The cost of granulocyte colony-stimulating factor (GCSF)
was from the NHS Trust. Other drug costs were assumed to
be included in the fee for an oncology consultation based
on dispensing location and consultation fee definitions.
For Australia, inpatient costs were found in the Aus-
tralian Government Department of Health and Ageing
Medicare Benefits Schedule Book [37]. Outpatient costs
were from the Australian Government Department of
Health and Ageing National Public Cost Weight
Tables [38]. Drug costs were from the Pharmaceutical
Benefits Scheme (PBS) [39].
For Canada, inpatient costs were from the Ontario Case
Costing Initiative (OCCI)—OCCI costing analysis tool
[40]. For costs not available in OCCI due to lack of data,
inpatient costs were from the Canadian Institute for Health
Information Patient Cost Estimator [41]. Outpatient costs
were from the Schedule of Benefits, Physician Services
under the Health Insurance Act [42]. Drug costs were from
the IMS Brogan database using the Association Que´be´coise
des Pharmaciens Proprie´taires (AQPP) prices [43].
To calculate outpatient and inpatient treatment of each
AE, unit costs were multiplied by default resource uti-
lization suggested by the clinical experts. A sensitivity
analysis was conducted by applying the unit costs to non-
base case resource utilization patterns in order to explore
the range suggested by the interviews.
Results
Forty-five publications on the pre-determined therapies
were derived from the literature search. From these studies,
a high-quality phase 3 study reporting grade 3 or 4 AEs for
each line of therapy was chosen. But if the line of therapy
was unclear or if a particular line of therapy had only phase
2 results published, phase 2 results were accepted; this was
the case for first line ipilimumab and second line IL-2 and
vemurafenib. Details of selected papers are reported in
Table 1.
A total of 30 (grade 3 or 4) AEs were identified from
these publications, excluding toxicities that would not
receive active management. Following the pilot interviews,
resource utilization patterns indicated that some AEs would
require a similar management approach or magnitude of
treatment. As a result, 17 clusters were created from the list
of AEs and the toxicity considered to be the most clinically
significant was selected as a proxy for the others; total
toxicity management costs were only estimated for the
proxy toxicity. The full list of AEs by their groupings is
presented in Table 2.
The most common grade 3 and 4 AEs included neu-
tropenia, vomiting and anemia for chemotherapy agents.
Vemurafenib was most commonly associated with cuta-
neous squamous cell carcinoma (CSCC)/keratocanthroma,
rash and elevated liver enzymes and dabrafenib was more
commonly associated with CSCC and pyrexia (fever).
Hypertension and rash were most often related to trame-
tinib. Common ipilimumab AEs were immune-related
diarrhea/colitis, dyspnea, anemia, vomiting, and
hypophysitis less frequently.
Base case outpatient costs are in Table 3. Inpatient
treatment costs for the management of AEs are reported in
Table 4. It was assumed that the inpatient cost for an AE
was the same in the grade 3 and grade 4 settings.
Results vary by country, reflecting variation in unit
costing across country borders, but trends appeared indi-
cating that hospitalization, outpatient procedures, and cer-
tain high-cost medications lead to expensive AE
management. Anemia required high-cost outpatient care
across all countries except for Germany due to use of
erythropoietin and/or blood transfusions. These costs range
from €936 (Netherlands) to €1443 (Spain), £730 (UK),
CAN$370 (Canada), and AUS$890 (Australia). Aside from
anemia, other costly outpatient AEs included CSCC in the
Netherlands (€1063), Germany (€406) and UK (£720),
febrile/afebrile neutropenia for Italy and Spain (€497–755),
peripheral neuropathy for Spain (€1289) and immune
related diarrhea for Australia (AUS$1121). In the Nether-
lands and Germany, the necessary outpatient excision of
CSCC drove the higher costs for that treatment, while
febrile/afebrile neutropenia expenditure was related to use
of granulocyte colony-stimulating factors (GCSF). Spe-
cialist consultations resulted in the high cost for peripheral
neuropathy in Spain while the cost for immunosuppressant
treatment contributed to the high cost of immune-related
diarrhea in Australia. See Table 3 for detailed cost results.
Hospitalizations weremore costly in general, but themost
expensive AEs to treat in the inpatient setting include
hypophysitis in Spain (€10,265), Canada (CAN$9735), and
Australia (AUS$7231), dyspnea inGermany (€9077), febrile
neutropenia in the UK (£4444), elevated liver enzymes in
France (€6913), fever in Italy (€3433), and peripheral neu-
ropathy in Netherlands (€6977). Febrile neutropenia was in
the top three most expensive hospitalizations in multiple
countries, as well, including Germany, Spain, Netherlands,
and UK (ranging from €2152 to €5480, or £4444 in UK). All
Euro-zone hospitalizations exceeded €1000 per episode,
while the lowest costs were approximately £1300 in UK,
AUS$1900 inAustralia, andCAN$3200 in Canada. Detailed
results can be found in Table 4.
As with base case results, country variation in sensitivity
analysis results exists as well. Due to cost-conserving
approaches to treatment, low ranges did not differ
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importantly from base case results across the countries, but
more expensive options were suggested for management of
certain AEs, with some notable trends, such as higher cost
medications suggested in lieu of base case treatment. Cost
of treating febrile or afebrile neutropenia could rise based
on the use of GCSF during treatment in Italy, Germany,
France, and the UK, with associated excess costs of
*€900, *€1400, *€3800, and *£240, respectively. In
Canada, use of antibiotics against febrile neutropenia could
inflate costs by approximately CAN$250. Use of erythro-
poietin products to treat anemia also resulted in higher
costs in Italy, France, Spain, and the Netherlands (over
€1000 more). The use of mycophenolate in Australia could
increase the cost of treating rash and palmar plantar
hyperkeratosis by as much as AUS$1000, as well.
Adding specialist consultations, facility stays, or pro-
cedures raised the total costs per AE as well. Additional
consultations increased the cost to treat neutropenia and
immune-related diarrhea in Canada by over CAN$1000 per
episode. Short facility stays in the UK led to higher costs of
managing grade 4 diarrhea and neutropenia of approxi-
mately £550-750. Transfusion procedures (thrombocyte or
Table 1 Summary of clinical studies on the treatment of metastatic melanoma for which grade 3 or 4 AEs were reported
Comparator Source study Study setting Phase Sample size (n) Treatment dose
Dabrafenib Hauschild [46] 1st line 3 187 150 mg twice daily orally
Dacarbazine Patel [47] 1st line 3 430 1000 mg/m2 on day 1 every 3 weeks
Fotemustine Avril [48] 1st line 3 112 Weekly for 3 consecutive weeks at 100 mg/m2 followed
by a 5-week rest period, with maintenance therapy for
nonprogressive patients of 100 mg/m2 every 3 weeks
IL-2 Tarhini [49] 2nd line 2 26 600,000 IU/kg per dose for a maximum of 14 doses per
cycle with a 1-week rest period between cycles.
Stable or responding patients were offered an additional
course after 6–8 weeks
Ipilimumab Hersh [50] 1st line 2 37 3 mg/kg once every 4 weeks for four treatments
Ipilimumab Hodi [8] 2nd line 3 137 3 mg/kg once every 3 weeks for four treatments
Temozolomide Patel [47] 1st line 3 429 Orally once a day at a dose of 150 mg/m2/day for seven
consecutive days every 2 weeks
Trametanib Flaherty [51] 2nd line 3 214 2 mg twice daily orally
Vemurafenib Chapman [52] 1st line 3 337 960 mg twice daily orally
Vemurafenib Sosman [53] 2nd line 2 132 960 mg twice daily orally
Table 2 List of toxicities


























Elevated liver enzymes Infection
Palmar-plantar hyperkeratosis Headache
Anemia
Bold AEs represent the group proxy, followed by other AEs in the group
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leukocyte) were costly additions to treatment for hemato-
logical toxicities in the Netherlands and France (€857 and
€629, respectively).
Discussion
Managing AEs resulting from metastatic melanoma
treatment can incur significant costs, even accounting
for variation in country-level or individual differences
in treatment approach. Payer-perspective costs of total
resources administered or recommended by a medical
oncologist or dermatologist (i.e., not including resour-
ces required for continuing care by another specialist),
ranged from the cost of an excess physician visit to
high hospitalization costs. This is a conservative
estimate of the resources used to treat toxicities related
to metastatic melanoma treatments; if other specialists
are consulted to manage specific events, for instance,
additional resources may be required that this study
does not capture.
Although differences existed across countries in item-
ized costs and treatment approaches, as well as in extent of
additional specialist consultation (see Appendix for
detailed resource utilization and cost values), some AE
management cost trends were apparent. In the outpatient
setting, anemia was one of the most costly AEs to treat in
most countries examined in this study. CSCC and immune-
related diarrhea were also costly in several countries. In the
inpatient setting, hypophysitis, elevated liver enzymes,
peripheral neuropathy, dyspnea, diarrhea, CSCC, and feb-
rile neutropenia incurred higher costs relative to other AEs
Table 3 Outpatient total costs required to manage AEs due to treatment for metastatic melanoma
Adverse event Grade Italy Spain Germany France Netherlands UK Australia Canada
Anemia 3 €1329 €1443 €46 €1285 €936 £730 $890 $370
4 €1281a €1443 €46 €1285b €936 £730 $890 $370
Cutaneous squamous cell carcinoma 3 €297 €297 €406 €71 €1063 £720 $424 $205
Diarrhea 3 €46 €134 €46 €33 €86 £251 $91 $162
4 €46 €134b €46 €33 €86 £126a $91 $162
Diarrhea (immune related) 3 €30 €134 €46 €29 €86 £251 $1121 $162
Dyspnea 3 €23 €99 €46 €156 €188 £251 $129b $194
4 €25 €99b c €156b d d $393b $194
Elevated liver enzymes 3 €47 €97 €46 €28 €79 £251 $304 $160
4 €47 €97 €46 €28 €79 £251 $304 $160
Febrile neutropenia 3 €436 €598 €46 €29 €81 d d $258
4 €436 €598 €46 €29 €81 d d $258
Fever 3 €21 €104 €46 €28 €82 £251 $94 $161
Headache 3 €255 €98 €46 €314 €82 £251 $99 $227
Hypertension 3 €46 €104 €61 €30 €79 £251 $97 $164
Hypophysitis 3 €326 €460 €46 €107 €465 £251 $283 $168
Infection 3 €34 €99 c €67 €81 £251 d $161
4 €34 €99b c €67 d £251 d $161
Neutropenia 3 €89 €598 €46 €28 €79 £251 $141 $160
4 €497 €755 €46 €28 €79 d $210 $160
Palmar plantar hyperkeratosis 3 €43 €173 €46 €28 €158 £126 $203 $160
Peripheral neuropathy 3 €173 €1289 €46 €28 €83 £126 $152 $183
4 €173 €1289 €46 €28 €83 £251 $218 $210
Rash 3 €47 €184 €46 €32 €86 £251 $380 $171
4 €47 €184b c €32 €82e £251 $373a $162f
Vomiting 3 €64 €132 €76 €31 €80 £251 $147 $239
4 €64 €132 c €31 €80 £251 d $239
a Grade 4 outpatient treatment is less expensive versus grade 3 because more physicians recommended patients be hospitalized in grade 4;
b Although clinicians provided outpatient resource use, they indicated that patients would always be hospitalized; c Never seen; d 100 % inpatient
admission; e Physicians suggested more prescription products for grade 3 versus grade 4; f Topical steroids for grade 3 were more expensive than
oral steroids for grade 4, as cream can only be purchased per tube
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related to melanoma treatments. AEs such as headache and
rash were among the least costly hospitalizations. These
trends reflect the higher unit costs associated with hospi-
talization, certain expensive medications, and procedures.
Some of the common AEs associated with ipilimumab
(hypophysitis, dyspnea, and diarrhea) and vemurafenib/
dabrafenib (CSCC and elevated liver enzymes) are among
the most expensive AEs.
A recent Italian retrospective cohort study investigated
the cost of unresectable stage III or stage IV melanoma,
providing some support for our findings in the Italian set-
ting [44]. Although Maio et al. do not report costs per
specific AE, they do investigate claims for drug therapies
associated with treating large categories of AEs that occur
in at least 5 % of the population. Categories of AEs in the
Maio analysis are based on type of drug therapy required
for treatment, including such drugs as ondansetron, dex-
amethasone, filgrastim, lenograstim and pegfilgrastim.
Maio et al. show similar prices per day for each drug as in
the current analysis, applied for slightly longer treatment
durations than in our analysis based on the average dura-
tion of therapy in their database. Although our analysis
supplements drug costs with other outpatient and inpatient
costs explicitly related to the adverse event, both analyses
demonstrate that managing AEs can require substantial
resources in Italy, suggesting that a melanoma regimen
with fewer and less costly AEs will ease some of the
burden faced by the patients with regionally or distantly
metastatic melanoma and the clinical community.
This study was designed to demonstrate that managing
each AE associated with melanoma treatment can be
costly; specific values presented in this study for multiple
country settings can be used in future analyses, including
modeling to assess the overall burden of managing AEs
over the course of therapy. Although not covered in this
study, a recent US retrospective database analysis investi-
gated the overall AE costs associated with several different
melanoma therapies (vemurafenib, ipilimumab, dacar-
bazine, paclitaxel and temozolomide). The authors found
that hemic and lymphatic disorders and effects incurred the
highest costs across therapies. Adjusted mean costs for AEs
were highest for dacarbazine and lowest for vemurafenib
among the treatments considered [45].
This study does have some limitations, however. The
study does not include pembrolizumab or nivolumab as these
products were not approved at the time of study completion;
however, AE profiles for these drugs do not require signifi-
cant additions to the already comprehensive list assessed in
this analysis. Moreover, although clinical trials may not
capture the set of real-world AEs, this source was considered
the most comprehensive and consistent source across ther-
apies under consideration and thus used to determine the list
considered in this study. Also, the resource use estimates in
this analysis may not represent the full spectrum of clinical
practice patterns or duration of required management across
all patients. This study depended on physician interviews to
derive resource use information, and five clinical experts
may not represent a nation’s practice patterns as a whole.
Table 4 Inpatient costs of treating grade 3 or 4 events due to treatment for metastatic melanoma
Adverse event Italy Spain Germany France Netherlands UK Australia Canada
Anemia €2667 €1801 €2367 €2000 €2839 £2246 $4380 $5181
Cutaneous squamous cell carcinoma €1589 €1221 €1544 €1416 €2122 £1692 $2379 $8934
Diarrhea €1456 €4113 €1348 €1585 €1456 £4284 $4572 $4320
Diarrhea (immune related) €1456 €4113 €1348 €1585 €1456 £4284 $4572 $4320
Dyspnea €1689 €1755 €9077 €1466 €1431 £1209 $3671 $5506
Elevated liver enzymes €2159 €3356 €1809 €6913 €1305 £1819 $6594 $8030
Febrile neutropenia €2357 €5480 €2388 €2000 €2152 £4444 $5224 $7843
Fever €3433 €2822 €1686 €1658 €1411 £1598 $4375 $5008
Headache €2366 €2489 €1644 €1002 €1718 £1372 $1935 $3479
Hypertension €1573 €2405 €2246 €1619 €1702 £3852 $4711 $7028
Hypophysitis €1589 €10,265 €1979 €5316 €1683 £2417 $7231 $9735
Infection €3433 €4477 €2099 €3018 €1806 £1918 $7199 $6563
Neutropenia €2357 €1529 €2388 €2000 €877 £2194 $5224 $7843
Palmar plantar hyperkeratosis €1308 €5121 €1544 – €1606 £1692 $2654 $4177
Peripheral neuropathy €1972 €4144 €2004 €2625 €6977 £2617 $4923 $9472
Rash €1308 €2087 €1544 – €1764 £1692 $2654 $3223
Vomiting €1456 €1755 €1348 €1585 €2045 £1702 $4572 $3543
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However, their responses serve to indicate some approaches
tomanagement, and the use of clinician agreement for a base
case estimate with sensitivity ranges to explore variation
creates a picture of the magnitude of financial impact in each
country. Additionally, only resources that would be used
from the medical oncologist or dermatologist’s perspective
were included. These estimates may not include additional
resources a specialist requires to continue management of an
AE, leading to potential underestimation of the total costs.
However, higher costs would only further support the sug-
gestion of sizeable AE-related cost burden. Regarding the
use of specific data sources, the cost estimates used in Spain
included both government costs and literature-based values,
as derived from the OBLIKUE database. Given the limited
nature of cost information in Spain, the OBLIKUE database
compiles the best available data sources, and therefore the
costs used in this study constitute the best representation of
the public payer perspective in Spain. Finally, this study does
not explore any indirect costs associated with advanced or
metastatic melanoma, as this analysis took the payer per-
spective in each country. Therefore, costs identified here
likely underestimate the true burden of melanoma in these
countries.
In light of these limitations, the findings from this analysis
should be interpreted with caution; results can be considered
an indication of the extent of the economic issue, aswell as an
initial understanding of the AE-specific costs per AE that
payers may face. As one of the only close examinations into
the size of global impact per AE, this initial financial picture
can help inform future evaluations of the clinical and cost-
effectiveness of treating patients with metastatic melanoma
while serving as an impetus for further study. As information
continues to accrue for the newest therapies in the coming
months and years, opportunities will exist to complement
this effort via future analysis of real-world resource use and
costs related to treating toxicities as a result of metastatic
melanoma therapy.
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